Table 2 Baseline characteristics
From: Comparative effectiveness of home dialysis therapies: a matched cohort study
Variable | Before matching (overall sample) | After matching | ||||
|---|---|---|---|---|---|---|
Home HD | PD | Standardized difference (%) | Home HD | PD | Standardized difference (%) | |
n = 3142 | n = 74,922 |  | n = 2668 | n = 2668 |  | |
Age (years), mean (SD) | 50.0 (14.6) | 56.3 (15.7) | 41.6 | 51.3 (14.3) | 51.4 (14.1) | 0.3 |
 18–29 years, % | 9.4 | 6.2 | 12.1 | 7.5 | 7.5 | 0 |
 30–39 years, % | 17.2 | 10.2 | 20.6 | 15.7 | 15.4 | 0.9 |
 40–49 years, % | 20.2 | 15.8 | 11.5 | 19.8 | 19.9 | 0.1 |
 50–59 years, % | 24.8 | 22.8 | 4.7 | 25.7 | 26.7 | 2.2 |
 60–69 years, % | 19.2 | 23.1 | 9.5 | 21.1 | 20.5 | 1.5 |
 70–79 years, % | 7.8 | 16.3 | 26.4 | 8.7 | 8.9 | 0.9 |
 >80 years, % | 1.5 | 5.8 | 23.2 | 1.5 | 1.2 | 2.9 |
Sex (male), % | 65.5 | 55.1 | 21.5 | 65.6 | 65.6 | 0 |
Race, % | ||||||
 White | 68.2 | 69.8 | 3.4 | 71.7 | 71.7 | 0 |
 Black | 28.1 | 23.6 | 10.2 | 25.9 | 25.9 | 0 |
 Other | 3.7 | 6.6 | 13.1 | 2.4 | 2.4 | 0 |
Smoking, % | 6.9 | 6.7 | 0.7 | 7.0 | 7.5 | 1.9 |
Alcohol, % | 0.5 | 0.7 | 1.9 | 0.6 | 0.8 | 3.1 |
Drugs, % | 0.4 | 0.5 | 0.8 | 0.5 | 0.9 | 5.5 |
Private coverage, % | 8.5 | 10.2 | 5.6 | 6.2 | 6.2 | 0 |
ESRD start date, % | ||||||
 ≤1976 | 0.1 | 0.1 | 0 | 0.1 | 0 | 1.3 |
 1977–1994 | 0.6 | 1.0 | 4.1 | 0.5 | 0.6 | 2.6 |
 1995–1999 | 5.8 | 1.6 | 21.3 | 3.2 | 3.1 | 0.5 |
 2000–2004 | 12.6 | 5.7 | 24.3 | 9.6 | 10.8 | 4.2 |
 2005–2009 | 74.9 | 73.5 | 3.2 | 80.1 | 79.5 | 1.5 |
 ≥2010 | 6.1 | 18.2 | 37.8 | 6.6 | 5.9 | 3.1 |
Duration of ESRD, mean (SD) | 2.9 (3.0) | 1.0 (2.5) | 70.2 | 2.4 (2.4) | 2.4 (2.4) | 1.6 |
 0–3 months, % | 1.3 | 66.4 | 189.5 | 1.5 | 1.5 | 0 |
 3–6 months, % | 11.0 | 6.4 | 16.4 | 12.3 | 12.3 | 0 |
 6–12 months, % | 17.5 | 6.0 | 36.5 | 19.0 | 19.0 | 0 |
 12–24 months, % | 22.4 | 6.4 | 46.7 | 24.5 | 24.5 | 0 |
 24–48 months, % | 23.8 | 8.8 | 41.5 | 26.3 | 26.3 | 0 |
 48–72 months, % | 11.3 | 2.3 | 36.6 | 9.3 | 9.3 | 0 |
 72–96 months, % | 5.3 | 1.2 | 23.0 | 3.0 | 3.0 | 0 |
 >96 months, % | 7.4 | 2.6 | 22.4 | 4.0 | 4.0 | 0 |
Weight (kg), mean (SD) | 90.5 (25.8) | 82.3 (21.4) | 34.4 | 88.5 (23.1) | 88.4 (23.0) | 0.1 |
Prior transplant, % | ||||||
 0 | 92.9 | 97.0 | 18.9 | 94.7 | 94.8 | 0.1 |
 1 | 6.4 | 2.7 | 17.9 | 4.8 | 4.9 | 0.1 |
 2 | 0.7 | 0.3 | 5.7 | 0.5 | 0.4 | 1.3 |
Comorbidities, % | ||||||
 Cancer | 5.7 | 5.0 | 3.0 | 6.0 | 4.3 | 7.8 |
 Hypertension | 83.9 | 86.4 | 7.2 | 84.0 | 85.6 | 4.4 |
 Congestive heart failure | 17.4 | 19.9 | 6.5 | 16.2 | 16.2 | 0 |
 Cerebrovascular disease | 3.8 | 5.9 | 9.7 | 4.0 | 4.7 | 3.5 |
 Peripheral vascular disease | 7.0 | 9.8 | 10.1 | 7.2 | 9.1 | 7.1 |
 Chronic obstructive pulmonary disease | 4.3 | 4.9 | 3.0 | 4.3 | 4.8 | 2.4 |
 Diabetes | 27.3 | 31.8 | 9.7 | 28.8 | 28.8 | 0 |
Laboratory values, mean (SD) | ||||||
 Albumin (g/dL) | 3.3 (0.7) | 3.4 (0.7) | 15.6 | 3.3 (0.7) | 3.2 (0.7) | 13.9 |
 Hemoglobin (g/dL) | 10.1 (1.7) | 10.4 (1.7) | 18.2 | 10.1 (1.7) | 10.0 (1.7) | 9.8 |